• Digital therapeutics (DTx) startup Sidekick Health and pharmaceutical company Eli Lilly have partnered to launch a DTx product for patients diagnosed with breast cancer. The digital product will offer a personalized treatment plan with behavioral modifications to improve wellbeing and support drug treatment adherence and side effects management.  

• The DTx will be tailored for patients treated with Lilly’s breast cancer medication including Verzenio, a CDK 4/6 inhibitor, which is expected to launch in Germany in July 2022. 

<ul><li> The latest collaboration comes hot on the heels of Sidekick’s partnership with Pfizer to develop a DTx solution targeting treatment adherence for atopic dermatitis or eczema. The company planned to announce three collaborations in the upcoming months following its funding round in May 2022 .</ul>